MX9800864A - Nuevos medicamentos y su utilizacion. - Google Patents

Nuevos medicamentos y su utilizacion.

Info

Publication number
MX9800864A
MX9800864A MX9800864A MX9800864A MX9800864A MX 9800864 A MX9800864 A MX 9800864A MX 9800864 A MX9800864 A MX 9800864A MX 9800864 A MX9800864 A MX 9800864A MX 9800864 A MX9800864 A MX 9800864A
Authority
MX
Mexico
Prior art keywords
action
ipratropium bromide
enantiomer
prolonged duration
salts
Prior art date
Application number
MX9800864A
Other languages
English (en)
Inventor
Rolf Banholzer
Richard Reichl
Bernd Disse
Georg Speck
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of MX9800864A publication Critical patent/MX9800864A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Debido a su sorprendentemente efecto fuerte y de larga duracion, las sales del enantiomero L-(-) de (endo, sin)-(-)-3-(3-hidroxi-1-oxo-2-fenilpropoxi)-8-meti l-8-)1-metiletil)-8-azoniabiciclo[3.2.1]octano son adecuados como principios activos para medicamentos de administracion por vía inhalativa para la terapia de las vías respiratorias.
MX9800864A 1995-08-01 1996-07-31 Nuevos medicamentos y su utilizacion. MX9800864A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19528145A DE19528145A1 (de) 1995-08-01 1995-08-01 Neue Arzneimittel und ihre Verwendung
PCT/EP1996/003364 WO1997005136A1 (de) 1995-08-01 1996-07-31 Ein enantiomer von ipratropiumbromid mit verlängerter wirkungsdauer

Publications (1)

Publication Number Publication Date
MX9800864A true MX9800864A (es) 1998-04-30

Family

ID=7768353

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9800864A MX9800864A (es) 1995-08-01 1996-07-31 Nuevos medicamentos y su utilizacion.

Country Status (37)

Country Link
US (1) US6299861B1 (es)
EP (1) EP0843676B1 (es)
JP (1) JPH11510150A (es)
KR (1) KR100445016B1 (es)
CN (1) CN1120841C (es)
AR (1) AR004179A1 (es)
AT (1) ATE208390T1 (es)
AU (1) AU6739796A (es)
BG (1) BG63780B1 (es)
BR (1) BR9609951A (es)
CA (1) CA2226934C (es)
CO (1) CO4750836A1 (es)
CZ (1) CZ291998B6 (es)
DE (2) DE19528145A1 (es)
DK (1) DK0843676T3 (es)
EE (1) EE04614B1 (es)
ES (1) ES2167592T3 (es)
HK (2) HK1013597A1 (es)
HR (1) HRP960365B1 (es)
HU (1) HU228056B1 (es)
IL (1) IL118986A (es)
MX (1) MX9800864A (es)
MY (1) MY115201A (es)
NO (1) NO317561B1 (es)
NZ (1) NZ315645A (es)
PL (1) PL183789B1 (es)
PT (1) PT843676E (es)
RO (1) RO120260B1 (es)
RU (1) RU2171258C2 (es)
SI (1) SI0843676T1 (es)
SK (1) SK283260B6 (es)
TR (1) TR199800121T1 (es)
TW (1) TW449597B (es)
UA (1) UA55391C2 (es)
WO (1) WO1997005136A1 (es)
YU (1) YU49479B (es)
ZA (1) ZA966494B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20020151541A1 (en) * 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6455028B1 (en) * 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
WO2002085296A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20050043343A1 (en) * 2003-07-28 2005-02-24 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
PE20060826A1 (es) * 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
WO2006114379A1 (de) * 2005-04-23 2006-11-02 Boehringer Ingelheim International Gmbh Arzneimittelkombination für die inhalation enthaltend neben einem anticholinergikum ein betamimetikum und ein steroid
US20060239935A1 (en) * 2005-04-23 2006-10-26 Boehringer Ingelheim International Gmbh Compositions for inhalation
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
TW201311649A (zh) * 2011-09-05 2013-03-16 Everlight Chem Ind Corp 用於太陽能電池電解液之化合物及其製法、含有該化合物之電解液及太陽能電池
CN111751454B (zh) * 2019-03-29 2023-12-08 天津药业研究院股份有限公司 一种异丙托溴铵中间体i的含量和有关物质的检测方法
CN110361494B (zh) * 2019-06-26 2023-08-15 四川普锐特药业有限公司 异丙托溴铵气雾剂中杂质g的检测方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505337A (en) * 1967-12-22 1970-04-07 Boehringer Sohn Ingelheim N - hydrocarbyl-substituted noratropinium,haloalkylates and o-acyl derivatives thereof
DE2903957A1 (de) * 1979-02-02 1980-08-07 Boehringer Sohn Ingelheim Mittel zur behandlung der nasalen hypersekretion
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4140861C2 (de) * 1991-12-11 2003-12-11 Boehringer Ingelheim Kg Verfahren zur Gewinnung von quartären Tropasäurealkaloiden
DK0673240T3 (da) * 1992-12-09 1999-10-11 Boehringer Ingelheim Pharma Stabiliserede medicinske aerosolopløsningsformuleringer

Also Published As

Publication number Publication date
DE19528145A1 (de) 1997-02-06
HUP9602104A3 (en) 2000-03-28
NZ315645A (en) 1999-11-29
HRP960365A2 (en) 1998-02-28
IL118986A (en) 1998-12-06
BR9609951A (pt) 1999-02-02
CA2226934A1 (en) 1997-02-13
AR004179A1 (es) 1998-11-04
TR199800121T1 (xx) 1998-04-21
DE59608156D1 (de) 2001-12-13
HU228056B1 (en) 2012-09-28
CZ225396A3 (cs) 1998-03-18
RU2171258C2 (ru) 2001-07-27
PT843676E (pt) 2002-04-29
IL118986A0 (en) 1996-10-31
BG63780B1 (bg) 2002-12-29
MY115201A (en) 2003-04-30
SK11298A3 (en) 1998-07-08
YU44596A (sh) 1998-12-23
ES2167592T3 (es) 2002-05-16
PL183789B1 (pl) 2002-07-31
CN1191535A (zh) 1998-08-26
ATE208390T1 (de) 2001-11-15
US6299861B1 (en) 2001-10-09
EE9800028A (et) 1998-08-17
EP0843676B1 (de) 2001-11-07
KR100445016B1 (ko) 2004-11-08
HK1010879A1 (en) 1999-07-02
HU9602104D0 (en) 1996-09-30
JPH11510150A (ja) 1999-09-07
HRP960365B1 (en) 2002-04-30
YU49479B (sh) 2006-05-25
EE04614B1 (et) 2006-04-17
NO980424D0 (no) 1998-01-30
BG102202A (en) 1998-09-30
CA2226934C (en) 2007-05-01
PL324804A1 (en) 1998-06-22
ZA966494B (en) 1997-02-03
CN1120841C (zh) 2003-09-10
HUP9602104A2 (en) 1997-04-28
DK0843676T3 (da) 2001-12-27
NO317561B1 (no) 2004-11-15
UA55391C2 (uk) 2003-04-15
SK283260B6 (sk) 2003-04-01
TW449597B (en) 2001-08-11
EP0843676A1 (de) 1998-05-27
HK1013597A1 (en) 1999-09-03
CZ291998B6 (cs) 2003-07-16
RO120260B1 (ro) 2005-11-30
AU6739796A (en) 1997-02-26
NO980424L (no) 1998-01-30
KR19990035997A (ko) 1999-05-25
WO1997005136A1 (de) 1997-02-13
SI0843676T1 (en) 2002-06-30
CO4750836A1 (es) 1999-03-31

Similar Documents

Publication Publication Date Title
MX9800864A (es) Nuevos medicamentos y su utilizacion.
MY129512A (en) Novel medicament compositions, based on tiotropium bromide and salmeterol
IL110084A (en) Therapeutic preparation for inhalation of insulin and process for its preparation
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
CA2375908A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
DK159805C (da) Medicinsk produkt indeholdende magnesiumtrisilicat, en fremgangsmaade til dets fremstilling samt praeparat indeholdende det medicinske produkt
CA2343123A1 (en) Active substance concentrate with formoterol, suitable for storage
AU4204389A (en) 3-(aminopropyl)methyl phosphinic acid as a therapeutic agent and intermediates in its synthesis
AU2916792A (en) Multilayer controlled release tablets containing both naproxen and naproxen sodium salt
CA2150185A1 (en) Pharmaceutical composition for the treatment of stoma-peripheral inflammation
CA2176298A1 (en) A single high dose fluoroquinolone treatment
AU693833B2 (en) Products containing G-CSF and TNF binding protein
CA2179015A1 (en) Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase
MX9805141A (es) Uso de inhibidores del intercambiador celular na+/h+ (nhe) para la preparacion de un farmaco para estimular la respiracion.
ZA963893B (en) Substituted benzyloxycarbonylguanidines, process for their preparation, their use as a medicament of diagnostic, and medicament containing them.
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
IL138855A0 (en) New treatments for nervous disorders
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
AU6432899A (en) Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
MY133438A (en) Morpholinobenzamide salts
GR3037039T3 (en) Use of trimetazidine for the preparation of medicaments for the treatment of troubles due to the therapeutical use of immunosuppressants.
HU9502320D0 (en) Use of inhibitors of ornitine aminotransferase for the manufacture of a medicament for the treatment of alzheimer&#39;s disease and process to prepare (2s,5s)-5-fluoromethylornithine
WO1994016705A3 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
MXPA03010920A (es) Uso de alconil l- carnitina para preparacion de medicamento para tratar anhedonia.